SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff has centered on concerns about its debt burden, distressed bond trading, and ability to finance its AI data-center expansion. Goldman Sachs Buy upgrade prompted hopes for a rebound, but traders debated whether the move could overcome financing risks, with bearish concerns about dilution or default competing with dip-buying and oversold-bounce calls.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention for its steep slide to fresh lows, as traders question the companys business prospects and debate whether Trumps political standing and the approaching midterms could further weaken its appeal. Sentiment is heavily bearish, though a few traders see the decline as a buying opportunity or cite possible merger and fusion developments.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs continued slide to fresh lows is being tied to soft residential roofing demand, housing-sector pressure and analyst target cuts, with traders also pointing to high rates and suspected dilution. Many are frustrated by the decline and managements limited communication, while some long-term holders remain optimistic about the building-products roll-up and future integration gains.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep selloff, with traders frequently citing insider selling and IPO lockup share releases as sources of supply pressure, alongside valuation and growth concerns. Bulls see an oversold AI-inference opportunity, while bears remain concerned about further selling, the companys ability to scale, and its reliance on OpenAI.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is drawing attention for its steep selloff and persistent underperformance, with traders citing weakness in crypto and AI infrastructure alongside concern about its CoreWeave tenancy and delays in securing additional data-center tenants. Many blame management and a lack of communication, while some remain hopeful that Helios revenue or earnings will demonstrate the businesss potential.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are under pressure amid a sustained selloff, with analyst caution and valuation concerns ahead of earnings adding to traders worries; some also point to broader market weakness and crypto declines. The bearish mood and speculation about insider selling or unusual activity contrast with dip-buyers who see the decline as an opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDAs acceptance of CorMedixs REZZAYO supplemental application for priority review in invasive fungal-disease prevention is drawing attention, with traders focused on the potential label expansion and upcoming regulatory decision. Enthusiasm is tempered by frustration that the news has barely moved the share price and broader concerns about DefenCaths reimbursement and competition; acceptance does not guarantee approval.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoin and broader crypto-market volatility are driving attention, with traders repeatedly criticizing COIN for falling sharply on weak crypto days while lagging during rebounds. Sentiment is split between frustration over its underperformance and hopes for a recovery, with upcoming quarterly results adding to the debate.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after its Phase 3 APOLLO trial of bitopertin met both primary and all secondary endpoints in erythropoietic protoporphyria, strengthening the case for an FDA resubmission after an earlier rejection. Traders are weighing the positive results and potential short-covering against profit-taking, heavy selling, and the remaining regulatory uncertainty.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs better-than-guided third-quarter results and upbeat outlook for higher EBITDA have driven a sharp rally, with traders also discussing potential short covering. Bulls see improving steel pricing and contracts supporting a recovery, while skeptics question whether the outlook can overcome the companys debt and past volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Equity

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Sept. 7, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no...

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July 29, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no...

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Sana (SANA) Upgraded to Buy: Here's What You Should Know

Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy PR Newswire LAS VEGAS, July...

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, June 2, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost...

Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum

Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum PR Newswire NEW YORK, May 28, 2026 USA News Group News CommentaryIssued on behalf ofAva Bio, Inc.As...

Sana Biotechnology (NASDAQ:SANA) Shares Down 7.3% - Time to Sell?

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 7.3% - Here's What Happened...

Wall Street Zen Downgrades Sana Biotechnology (NASDAQ:SANA) to Strong Sell

Wall Street Zen lowered Sana Biotechnology from a "sell" rating to a "strong sell" rating in a research note on Saturday...

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Sana Biotechnology Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Lilly will present Phase 2 results for its eloraTZP combination at the EASD meeting in Milan.</li><li>SAB BIO, Sana and Century will present type 1 diabetes research at different stages of development.</li><li>uniQure expects a four-year AMT-130 update by quarter-end and Scynexis has guided to two Phase 1 updates.</li></ul><p>Biotech investors face a crowded final week of September as Eli Lilly (LLY) and Novo Nordisk (NVO) bring their latest obesity and diabetes research to a major medical meeting in Milan, while uniQure (QURE) and Scynexis (SCYX) approach quarter-end targets for clinical updates that could put smaller stocks in the spotlight.&nbsp;</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 1.8% last week, outperforming the broader market’s<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which rose 1.3%, but trailing the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, which climbed 3.3%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> advanced 2.6%, beating both <a class="mention" data-mention="$XLV" data-symbol-id="XLV" href="https://stocktwits.com/symbol/XLV" target="_blank">XLV</a> and SPY while lagging QQQ. The<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> fell 1.1%.&nbsp;</p><p><img src="https://news.stocktwits-cdn.com/healthcare_fef01ed028.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/ Event</td><td>Development</td></tr><tr><td>Sept.28</td><td>CAMP</td><td>Camp4 Therapeutics holds an analyst day on its CMP-002 trial for SYNGAP1-related disorder.</td></tr><tr><td>Sept.28-Oct.2</td><td>EASD</td><td>Lilly, Novo and smaller biotech companies present diabetes and obesity research in Milan.</td></tr><tr><td>Sept.29</td><td>NVO, KURA</td><td>Novo presents CagriSema analyses, while Kura affiliate Caspian Therapeutics presents preclinical KO-7246 research.</td></tr><tr><td>Sept.30</td><td>LLY, NVO, SABS</td><td>Lilly presents Phase 2 eloraTZP results; Novo has several pipeline sessions; SAB BIO discusses SAB-142.</td></tr><tr><td>By Sept.30</td><td>QURE, SCYX</td><td>Potential four-year AMT-130 update from uniQure and two Phase 1 topline updates from Scynexis.</td></tr><tr><td>Oct.1</td><td>LLY, FDA</td><td>Lilly presents Foundayo data; an FDA panel discusses influenza vaccine strain selection.</td></tr><tr><td>Oct.2</td><td>SANA, IPSC</td><td>Sana and Century present separate type 1 diabetes cell-therapy programs.</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Lilly, Novo Put Next Obesity Drugs On Display&nbsp;</strong></h2><p>The European Association for the Study of Diabetes’ annual meeting runs Monday through Friday in Milan, with obesity and diabetes presentations from Eli Lilly and Novo Nordisk. The program also includes type 1 diabetes research from SAB BIO (SABS), Sana Biotechnology (SANA) and Century Therapeutics (IPSC).<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.easd.org/annual-meeting/?utm_source=chatgpt.com">&nbsp;</a></p><p>On Wednesday, Lilly will present Phase 2 results for eloraTZP, a combination of the amylin-targeting drug Eloralintide and Tirzepatide, the ingredient in Mounjaro and Zepbound. The study involves adults with obesity or overweight and type 2 diabetes. Lilly will also discuss Phase 3 findings for Retatrutide, which targets three hormone receptors, and results from Surpass-CVOT, a study of Tirzepatide’s cardiovascular outcomes. Thursday’s session covers Phase 3 findings for its oral diabetes drug Foundayo, or Orforglipron. Lilly has already disclosed headline results from several of these studies and the presentations will add more details.</p><p>Novo has 44 abstracts at the meeting. Tuesday’s presentations include Reimagine 1 analyses of CagriSema’s effects on body composition and combined blood-sugar and weight-loss goals. On Wednesday, Novo will discuss CagriSema’s effects on appetite and responses to food cues, and present Phase 2b results for Zenagamtide, also known as Amycretin.</p><h2 class="st-heading-2"><strong>Smaller Biotechs Target Type 1 Diabetes&nbsp;</strong></h2><p>SAB BIO (SABS) will present research on SAB-142, an immunotherapy for type 1 diabetes, on Monday and Wednesday. Its Phase 1 findings address repeat dosing and early C-peptide signals. C-peptide helps show how much insulin a patient’s body still produces.</p><p>Friday features two cell-therapy programs at different stages. Sana Biotechnology (SANA) will discuss findings from a first-in-human study involving engineered donor insulin-producing cells transplanted into one patient without immunosuppressive drugs. Century Therapeutics (IPSC) will present preclinical research on manufacturing engineered stem-cell-derived insulin-producing cells for its CNTY-813 program.&nbsp;</p><p>Kura Oncology (KURA) is also linked to the diabetes program. Its separately financed affiliate, Caspian Therapeutics, will present Tuesday on KO-7246, an experimental drug being studied for its potential to increase insulin-producing beta cells.&nbsp;</p><h2 class="st-heading-2"><strong>Beyond Milan: 3 More Events To Watch This Week&nbsp;</strong></h2><p>Sellas Life Sciences (SLS) is also in focus as the AACR pancreatic-cancer conference concludes on Monday. The company released preclinical findings on its experimental drug SLS009 on Friday, ahead of three poster presentations&nbsp;that happened on Sunday. The studies examined SLS009 in pancreatic-cancer models, including combinations designed to address treatment resistance.</p><p>Camp4 Therapeutics (CAMP) has a confirmed event on Monday. Its analyst day will cover the design of a first-in-human Phase 1/2 trial of CMP-002 for Syngap1-related disorder. CAMP4 expects to start the trial in the fourth quarter.</p><p>Meanwhile, the FDA’s vaccine advisory committee is scheduled to meet on Thursday to recommend influenza virus strains for vaccines intended for the 2027 Southern Hemisphere season. Its recommendations are nonbinding.</p><h2 class="st-heading-2"><strong>Quarter-End Data Clock Ticks For QURE, SCYX&nbsp;</strong></h2><p>Outside the conference, uniQure (QURE) intends to present a four-year analysis of its AMT-130 gene-therapy studies in Huntington’s disease before the third quarter ends on Wednesday. The firm’s earlier guidance said the update would include four years of follow-up on 24 patients in its first two treatment cohorts.&nbsp;</p><p>uniQure submitted AMT-130 applications to U.S. and U.K. regulators earlier this month, supported by an earlier three-year analysis. The pending four-year update is a separate milestone. The company has requested priority review in the U.S.</p><p>Additionally, Scynexis (SCYX) has guided to two Phase 1 topline updates in the third quarter. Results for SCY-770, a potential treatment for inherited polycystic kidney disease, are expected to help select doses for a Phase 2 study. The other update concerns an intravenous version of SCY-247, an experimental antifungal.&nbsp;</p><h2 class="st-heading-2"><strong>Moderna’s Melanoma Details Remain Pending&nbsp;</strong></h2><p>Moderna (MRNA) and Merck (MRK) announced in August that their Phase 3 INTerpath-001 trial met its goals for delaying melanoma recurrence and the spread of cancer to distant parts of the body. The trial tested Moderna’s individualized cancer treatment Intismeran with Merck’s Keytruda after patients’ tumors had been surgically removed.&nbsp;</p><p>Investors are still awaiting the detailed results. The companies plan to present them at an “international medical meeting,” but have not named the conference or date.&nbsp;</p><h2 class="st-heading-2"><strong>LLY, NVO, QURE: How Do Retail Traders Feel?</strong></h2><p>Retail traders on Stocktwits turned more upbeat on LLY and QURE, even as chatter cooled. Sentiment on LLY improved to ‘neutral’ from ‘bearish’ over the past week, while message volume fell 10%. QURE sentiment rose to ‘bullish’ from ‘neutral’ a week ago, despite a 33% drop in 24-hour message volume.&nbsp;</p><p>NVO drew the most optimistic response: sentiment was ‘extremely bullish’ as message volume surged 100% over the past week.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stla-f-gm-trump-fuel-economy-rollback-auto-plants-coming-back/cZMSWm8RBfh">STLA, F, GM Climb Overnight As Trump Clears Fuel Economy Rollback — Says Auto Plants Are ‘Coming Back’&nbsp;</a></p>

Representative Image (Photo credit: Getty Images)

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch

iShares Biotechnology ETF

Century Therapeutics Inc

Lilly(Eli) & Co

Merck & Co Inc

Moderna Inc

Novo Nordisk A/S

uniQure NV

SAB Biotherapeutics Inc

Scynexis Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$2.26
Prev Close	$2.27
Open	$2.32
Dividend Yield	0.00%
50-Day Moving Average	$3.29
Beta	2.10
Avg. Volume	3.91M
PE Ratio	-2.98

52-Week High	$5.90
52-Week Low	$2.25
Market Capitalization	$679.55M
EPS (Annual)	-$0.9642
Price to Book	4.40
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SANA Fundamentals